WEP Clinical (WEP) announced today that it has extended its partnership with BTG Specialty Pharmaceuticals (BTG), a division of Boston Scientific. Last year, WEP announced it would be partnering with BTG to supply the company’s medicine, Voraxaze®, to patients in Europe, through a Named Patient Program (NPP). Following the initial success of this first program, WEP has now been awarded ex-US* distribution rights for Voraxaze® and another BTG rescue medicine, DIGIFab® (digoxin immune Fab).

DIGIFab® is a sterile, purified, lyophilized preparation of digoxin immune Fab (ovine). It is used to treat patients with known or strongly suspected life-threatening digoxin toxicity. DIGIFab® binds to molecules of digoxin thereby reducing free digoxin levels and resolving the cardiotoxic effects and other clinical manifestations of life-threatening digoxin toxicity.

DIGIFab® has been approved for use in certain countries, including the US in 2001 and the UK in 2011. WEP will manage the licensed supply of DIGIFab® in the UK.

WEP will also manage the supply of this product on an unlicensed basis, through an NPP, in countries where approval has not yet been granted. This excludes any countries subject to sanctions, embargoes or restrictions imposed by the United Nations, the European Union, the Organization for Security and Co-operation in Europe and/or the Office of Foreign Assets Control. This will allow physicians to treat patients who, otherwise, would have no effective treatment options available to them domestically.

If you are a healthcare professional in a country where DIGIFab® is licensed and you would like to learn more about the product, please visit www.digifab.health.

Jas Khera, Managing Director of WEP Clinical, said:

“We are delighted to extend our partnership with BTG Specialty Pharmaceuticals and help additional patients around the world access much-needed rescue medicines. Our team has over a decade of experience making products like DIGIFab® and Voraxaze® available in many countries worldwide, on an unlicensed basis. Our strong project management focus ensures that our programs are delivered in a manner that is flexible, efficient, and robust. We believe that being awarded this second program with BTG highlights WEP Clinical’s commitment to providing a best-in-class service for our sponsor companies and the patient populations they serve.”

*DIGIFab® ex-US distribution rights exclude Australia, Canada, Liechtenstein, New Zealand, Saudi Arabia, Switzerland and the United States of America. Voraxaze® ex-US distribution rights exclude Australia, New Zealand, Japan and the United States of America.

About WEP Clinical

Established in 2008, WEP is a specialist pharmaceutical services company that works with sponsors to help patients and physicians gain access to medicines when there is no treatment available in their country. WEP Clinical is a global organisation and possesses all necessary licenses required to meet drug access and distribution needs across all regions, worldwide.

About BTG Specialty Pharmaceuticals

BTG Specialty Pharmaceuticals, a division of Boston Scientific, provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. We are dedicated to the development, manufacture, and commercialization of quality medicines that make a real difference to patients and their families. Our current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. To learn more, please visit: btgsp.com.